Hers vs MEDVi: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
MEDVi beats Hers overall, scoring 7.7/10 vs 7.3/10. MEDVi is more affordable at $299/mo vs $348/mo. Choose Hers for women who want glp-1 access from a well-known, publicly trad. Choose MEDVi for users who want a low entry price with oral and injectable co.
A side-by-side comparison of Hers and MEDVi covering pricing, scores, medication types, insurance, and more to help you decide.
Hers
#33 of 40The women's health arm of Hims & Hers Health (NYSE: HIMS), offering compounded GLP-1 medications with a polished app experience designed for women's health needs.
Visit HersMEDVi
#21 of 40Compounded GLP-1 platform offering both oral and injectable options with flexible dosing and affordable pricing.
Visit MEDVi| Feature | Hers | MEDVi |
|---|---|---|
| Our Score | 7.3/10 | 7.7/10 |
| Starting Price | $348/mo | $299/mo |
| Medication Type | Compounded | Compounded |
| Insurance Accepted | No | No |
| Best For | Women who want GLP-1 access from a well-known, publicly traded telehealth brand | Users who want a low entry price with oral and injectable compounded options |
| Ranking | #33 | #21 |
Pros & Cons Compared
Hers
Pros
- +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
- +Women-focused branding, content, and support — not a men's health platform with a women's tab
- +$199/mo all-inclusive for compounded semaglutide with consultations and free shipping
- +Broader women's health platform — can address hormonal, skin, and wellness needs alongside weight loss
Cons
- −Pivoted away from some compounded formulations after FDA crackdown — medication availability can shift
- −Compounded only — no brand-name Wegovy or Zepbound through the platform
- −Generic support experience — large patient volume means less personalized attention
- −Higher price than competitors like TrimRx ($179) or Enhance MD ($115) for a similar compounded product
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179/mo is competitive for a platform with both oral and injectable compounded formulations
Cons
- −Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Our Verdict
MEDVi edges out Hers with a score of 7.7/10 vs 7.3/10. If budget is your priority, MEDVi starts at $299/mo compared to Hers's $348/mo. Choose Hers if you want: women who want glp-1 access from a well-known, publicly traded telehealth brand. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.